- Home
- VCNX vs MTEM Comparison
VCNX vs MTEM Comparison
Compare VCNX & MTEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VCNX
- MTEM
- Stock Information
- Founded
- VCNX 2001
- MTEM 2001
- Country
- VCNX United States
- MTEM United States
- Employees
- VCNX N/A
- MTEM N/A
- Industry
- VCNX Biotechnology: Pharmaceutical Preparations
- MTEM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VCNX Health Care
- MTEM Health Care
- Exchange
- VCNX Nasdaq
- MTEM Nasdaq
- Market Cap
- VCNX 10.5M
- MTEM 9.7M
- IPO Year
- VCNX N/A
- MTEM N/A
- Fundamental
- Price
- VCNX $1.41
- MTEM $0.36
- Analyst Decision
- VCNX
- MTEM
- Analyst Count
- VCNX 0
- MTEM 0
- Target Price
- VCNX N/A
- MTEM N/A
- AVG Volume (30 Days)
- VCNX 96.1K
- MTEM 15.2M
- Earning Date
- VCNX 11-14-2024
- MTEM 12-27-2024
- Dividend Yield
- VCNX N/A
- MTEM N/A
- EPS Growth
- VCNX N/A
- MTEM N/A
- EPS
- VCNX N/A
- MTEM N/A
- Revenue
- VCNX $388,000.00
- MTEM $25,470,000.00
- Revenue This Year
- VCNX N/A
- MTEM N/A
- Revenue Next Year
- VCNX N/A
- MTEM N/A
- P/E Ratio
- VCNX N/A
- MTEM N/A
- Revenue Growth
- VCNX N/A
- MTEM N/A
- 52 Week Low
- VCNX $1.25
- MTEM $0.30
- 52 Week High
- VCNX $13.02
- MTEM $4.12
- Technical
- Relative Strength Index (RSI)
- VCNX 27.23
- MTEM 42.73
- Support Level
- VCNX $3.34
- MTEM $0.34
- Resistance Level
- VCNX $4.35
- MTEM $0.78
- Average True Range (ATR)
- VCNX 0.45
- MTEM 0.07
- MACD
- VCNX -0.19
- MTEM 0.01
- Stochastic Oscillator
- VCNX 0.00
- MTEM 7.49
About VCNX Vaccinex Inc.
Vaccinex Inc is pioneering a differentiated approach to treating cancer and slowly progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). The company's lead drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that it believes prevents immune infiltration into tumors and triggers inflammation in chronic diseases of the brain. Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease. The firm has also developed a proprietary drug discovery platform, ActivMAb.
About MTEM Molecular Templates Inc.
Molecular Templates Inc is a clinical-stage biopharmaceutical company focused on developing therapeutic agents that selectively target tumor cells for the treatment of individuals living with cancer. Its pipeline products are MT-6402, MT-8421 and MT-0169.